Sysmex Corporation

Other

The University of Texas System

Hideki Ishihara

Tomoko Matsushima

Masaki Shibayama

Yuko Kawasaki

Satoshi Nakayama

Masahiro Kajita

Satoshi Tanaka

Shigehiro Numada

Koichi Yamagata

Ayako Sakai

Noriko Oka

Aya Katayama

Manfred Schmitt

Toshiyuki Sakai

Hironori Kobayashi

Tomokazu Yoshida

Yasushi Hasui

Sachiyo Tada

Yuichi Yasuda

Naoto T Ueno

Masatoshi Yamasaki

Masaya Tohyama

Noriaki Yamamoto

Michitaka Notoya

Tadashi Kiniwa

Keigo Gohda

Ulrike Schwarz-Boeger

Rupert Langer

Tamotsu Sudo

Yasuhiro Torikoshi

Marion Kiechle

Tomoko Ohyama

Masaaki Kawai

Jun Sato

There is provided a method of judging a risk of cancer recurrence based on the activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and the expression levels of uPA and PAI-1 and a computer program.

Method of judging risk of cancer recurrence and computer program

A diagnosis support system for cancer is disclosed that comprises: a measurement value acquiring section for acquiring a measurement value of a first cancer patient; a sample data memory for storing sample data of a plurality of cancer patients different from the first patient; a reference range determination section for determining a reference range based on the measurement value of the first cancer patient; a display unit; and a display controller for controlling the display unit to display a diagnosis support screen showing the clinical information included in the sample data having measurement value within the reference range. A method of providing cancer diagnosis support information and a computer program product are also disclosed.

Diagnosis support system for cancer, diagnosis support information providing method for cancer, and computer program product

A CDK profile including a ratio of specific activities of two cyclin dependent kinases closely correlates with the malignancy grade and the presence/absence of the sensitivity to an irritant such as an anticancer agent of a cancer tissue in clinical medicine. Therefore, the properties of a mammalian cell, such as malignancy grade, proliferation potency, sensitivity to an irritant such as an anticancer agent can be assessed based on its CDK profile or by comparing the result of a specific activity ratio of two CDKs with a predetermined threshold corresponding to the ratio. This sensitivity assessing method shows a high ratio of correct assessing results particularly in positive or sensitivity and is useful in predicting efficacy of chemotherapy using the anticancer agent.

Method of assessing properties of mammalian cells, and method of diagnosing cancer using the same

A method for judging a risk of cancer recurrence comprising: acquiring an activity value and expression level of a first cyclin dependent kinase (CDK) of a cell contained in tissues extracted from cancer patients, an activity value and expression level of a second CDK, and a number of Ki67-expressing cells or an expression level of Ki67; and judging a risk of cancer recurrence based on the acquired activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and a percentage of Ki67-expressing cells or the expression level of Ki67. A computer program product and a computer system are also disclosed.

Method for judging risk of cancer recurrence, computer program, and computer system

The method for detecting a methylated cytosine of the present invention comprises the steps of:

Method of detecting methylated cytosine

A method for detecting integrated HPV DNA is described herein. This method comprises obtaining first and second samples, obtaining first and second information, and detecting, based on the first and second information, the HPV DNA integrated into the genome of a cell derived from a subject. The second sample comprises DNA derived from the cell, which is treated with an enzyme having exonuclease activity. The first information is related to the amount of HPV DNA in the first sample, and the second information is related to the amount of HPV DNA in the second sample.

Method for detecting integrated HPV DNA

The present invention provides a method of analyzing methylated DNA, comprising steps of: (A) treating a DNA-containing sample with a restriction enzyme to obtain a sample containing a DNA fragment; (B) concentrating methylated DNA contained in the sample obtained in step (A) to obtain a methylated DNA concentrate; (C) subjecting the methylated DNA concentrate obtained in step (B) and a primer set to nucleic acid amplification reaction, wherein the primer set performs the nucleic acid amplification reaction in step (C) by using a template DNA which does not have a CpG site; (D) detecting an amplification product obtained in step (C); (E) judging whether the methylated DNA concentrate obtained in step (B) is appropriate as a sample for detection of methylated DNA, on the basis of the detection result of the amplification product in step (D); and (F) analyzing the methylated DNA contained in the methylated DNA concentrate.

Method of analyzing methylated DNA

A method of supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs is disclosed. The method provides a new value for judging an effect, a judgment score, which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The effect of the treatment by using anthracycline anticancer drugs is judged by comparing the judgment score with a predetermined threshold level.

Method for supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs and a device for supporting a diagnosis for an effect of a treatment by using anthracycline anticancer drugs

A device for supporting a diagnosis of a cancer which provides information useful to decide whether or not an anthracycline anticancer drug should be administered to a cancer patient to be examined is disclosed. Concretely, the device is composed to be able to acquire an activity and an expression of two cyclin dependent kinases (CDK) from a malignant tumor of a cancer patient to be examined, and to acquire a CDK parameters from both of two CDKs. Furthermore the device determines sample data comprising predetermined CDK parameter, and display information of determined sample data. According to the above component, user is easily able to know whether or not a cancer of a cancer patient, whose tumor is similar to the tumor of the cancer patient to be examined, has been recurred in spite of an administration of an anthracycline anticancer drug.

Cancer diagnostic device

A method for judging feature of malignant tumor is described. The method comprises obtaining step, first comparing step, second comparing step and judging step. The obtaining step comprises obtaining a first parameter based on activity and expression level of a first cyclin dependent kinase (first CDK) contained in a tumor cell of the malignant tumor, a second parameter based on activity and expression level of a second cyclin dependent kinase (second CDK) contained in the tumor cell, a third parameter based on the first parameter and the second parameter, and a fourth parameter based on expression level of a cyclin contained in the tumor cell. The first comparing step comprises comparing a first threshold value with the third parameter. The second comparing comprises comparing a second threshold value with the fourth parameter. The judging step comprises judging the feature of the malignant tumor based on the comparison results of the first comparing step and the second comparing step.

Method for judging feature of malignant tumor

The present invention provides a method for determining the chemosensitivity of a cancer cell to a taxane comprising assessing the effect of the taxane on the expression level or activity of one or more cell cycle molecules in a cancer cell. Such a method makes use of an automated analyzer system wherein cell cycle parameters (molecules) such as CDK1 kinase activity, CDK1 expression, CDK2 kinase activity, CDK2 expression, MAD2 expression, Cyclin B1, Cyclin E expression, p21 expression, and CDK6 expression; are assessed. The present invention further provides a method of obtaining a cell cycle profile of a cancer cell that is sensitive to a taxane.

Taxane chemosensitivity prediction test

A method of supporting a diagnosis of a risk of cancer recurrence is disclosed. The method provides a new determining value a recurrence risk score (RRS) which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The risk of cancer recurrence is judged by comparing the RRS with a predetermined threshold level for RRS.

Method of supporting a diagnosis of a risk of cancer recurrence, and a device of supporting a diagnosis of a risk of cancer recurrence

A method for predicting an effectiveness of chemotherapy is described. The method comprises a comparing step and a predicting step. The comparing step is a step of comparing a threshold value with a parameter of a cyclin dependent kinase (CDK) included in a sample containing a tumor cell obtained from a human patient. The predicting step is a step of predicting the effectiveness based on a comparison result of the comparing step. Above stated parameter is selected from the group consisting of an activity, an expression level, and a ratio of activity to expression level.

Method for predicting effectiveness of chemotherapy

A reagent kit that is used for determining a characteristic of tissue obtained from a patient is described. The reagent kit comprising expression measurement reagents for measuring expression level of cyclin-dependant kinase (CDK) and activity measurement reagents for measuring activity value of CDK. The expression measurement reagents comprise first reagents and second reagents, and the activity measurement reagents comprise third reagents and fourth reagents. In the reagent kit, a first reagent set of the first and third reagents is stored under a first storage condition relating to temperature, and a second reagent set of the second and fourth reagents is stored under a second storage condition relating to temperature.

Reagent kit for determining characteristic of tissue

The tissue characteristic determination apparatus capable of determining the characteristics of the tissues collected from a living organism is described, a representative one of which includes: a first data obtainer for obtaining first data reflecting the activity of first cyclin-dependent kinase contained in samples prepared from the tissues, a second data obtainer for obtaining second data reflecting the expression level of the first cyclin-dependent kinase, and a tissue characteristics information obtainer for obtaining information on the characteristics of the tissues based on first values obtained from the first and second data.

Growing community of inventors

Miki, Japan

Hideki Ishihara